Results 21 to 30 of about 26,055 (166)
Recuerdo entrañable de un buen médico y de un médico bueno: Fernando Hernández Navarro [PDF]
, 2009 Sin ...
Arranz Carrillo del Albornoz, Pilar +1 more
core +1 more source
HemaSphere, Volume 10, Issue 5, May 2026.Abstract Recent clinical trials have underscored the value of repeated minimal residual disease (MRD) measurements as a highly sensitive method for detecting subclinical disease and enabling dynamic risk stratification in hematologic malignancies. Despite its clinical potential, the complex and heterogeneous nature of MRD kinetics presents significant ...
Francesca Cordero +27 more
wiley +1 more source
Tiempo de recaída posterior a quimioterapia de inducción en niños con leucemia linfoblástica aguda atendidos en un hospital nacional de Chiclayo [PDF]
, 2020 OBJETIVO: analizar el tiempo de recaída posterior a quimioterapia de inducción en niños con leucemia linfoblástica aguda (LLA) atendidos en un hospital nacional de Chiclayo. MÉTODO: Estudio observacional analítico de una cohorte retrospectiva.
Burga Guevara, Diana katherine +1 more
core
HemaSphere, Volume 10, Issue 4, April 2026.Abstract Arginine residues in antithrombin are essential for heparin binding and for the activation of this key anticoagulant serpin. Mutations affecting these residues may cause antithrombin deficiency, specifically Type II heparin‐binding site (HBS) defects, and increase the risk of thrombosis.
Rosa Cifuentes‐Riquelme +11 more
wiley +1 more source
Pronóstico del compromiso de médula ósea en pacientes con linfoma no Hodgkin Hospital Militar Bogotá [PDF]
, 2013 Los linfomas no Hodgkin pueden tener un comportamiento diferente de acuerdo a la presencia de compromiso tumoral en la médula ósea, sin embargo no todos los estudios han reportado hallazgos similares en este aspecto.
Lombana Quiñonez, Milton Alberto +1 more
core
eJHaem, Volume 7, Issue 2, April 2026.ABSTRACT Objectives Targeted therapies have markedly improved outcomes in chronic lymphocytic leukaemia (CLL), particularly among patients with TP53 alterations and unmutated IGHV. However, real‐world studies report persistent inequalities in access to optimal care.
Susana Esteves +7 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 4, Page 435-442, April 2026.ABSTRACT Background In the earlier PROTECT VIII Kids study (NCT01775618), damoctocog alfa pegol was efficacious for prevention and treatment of bleeds in children aged < 12 years with severe haemophilia A. Objective Assess the safety of damoctocog alfa pegol, including hypersensitivity and loss of efficacy (LoE) due to an immune response to ...
Margareth C. Ozelo +13 more
wiley +1 more source
Enfermedad de Gaucher en Argentina: un informe del Registro Internacional de Gaucher y del Grupo Argentino de Diagnóstico y Tratamiento de la Enfermedad de Gaucher [PDF]
, 2013 La Enfermedad de Gaucher por su baja frecuencia está incluida dentro de las enfermedades huérfanas. En 1991 comenzó el ingreso de pacientes en el Registro Internacional de Gaucher. En 1992 se incorporaron los primeros dos pacientes de Latinoamérica.
Angaroni, Celia Juana +25 more
core
European Journal of Haematology, Volume 116, Issue 4, Page 471-472, April 2026.ABSTRACT This is a plain language summary describing results from the Alfa‐PROTECT study on safety and efficacy of damoctocog alfa pegol in previously treated children aged between 7 and 12 years with severe haemophilia A.
Margareth C. Ozelo +13 more
wiley +1 more source